Matthew Winton
2023
In 2023, Matthew Winton earned a total compensation of $1.5M as Senior Vice President and Chief Operating Officer at Inozyme Pharma.
Compensation breakdown
| Bonus | $50,000 |
|---|---|
| Non-Equity Incentive Plan | $150,000 |
| Option Awards | $1,022,196 |
| Salary | $326,250 |
| Other | $181 |
| Total | $1,548,627 |
Winton received $1M in option awards, accounting for 66% of the total pay in 2023.
Winton also received $50K in bonus, $150K in non-equity incentive plan, $326.3K in salary and $181 in other compensation.
Rankings
In 2023, Matthew Winton's compensation ranked 744th out of 2,821 executives tracked by ExecPay. In other words, Winton earned more than 73.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 744 out of 2,821 | 74th |
Division Manufacturing | 434 out of 1,551 | 72nd |
Major group Chemicals And Allied Products | 299 out of 877 | 66th |
Industry group Drugs | 293 out of 840 | 65th |
Industry Pharmaceutical Preparations | 194 out of 605 | 68th |
Source: SEC filing on April 26, 2024.
Winton's colleagues
We found three more compensation records of executives who worked with Matthew Winton at Inozyme Pharma in 2023.